OPERS Federal Comment Letters
OPERS has a significant interest in the regulatory process at the federal level.
Staff actively comment and participate in the development of federal regulations specifically in health care, investments, and corporate governance.
Below are comment letters submitted by OPERS to various agencies such as the FDA, CMS, IRS, and HHS.
- OPERS comment letter to the FDA: Facilitating Competition and Innovation in the Biological Products Marketplace
(Sept. 21, 2018) - OPERS Comment Letter - American Patients First
(July 16, 2018) - OPERS Comment Letter - FDA – Oncologic Drugs Advisory Committee
(May 3, 2017) - OPERS Comment Letter to the FDA - Biosimilar Interchangeability
(March 10, 2017) - Letter of Support for PRICED Act Biosimilars Bill
(Sept. 26, 2016) - Public Sector Health Care Roundtable Letter Regarding Increased Medicare Part B Premiums
(Sept. 27, 2016) - OPERS Comment Letter to the Centers for Medicare and Medicaid Services (CMS) - Expansion of the Medicare Diabetes Prevention Program (DPP)
(Sept. 6, 2016) - OPERS Comment Letter - FDA - Arthritis Advisory Committee
(June 28, 2016) - OPERS Comment Letter - FDA - Biosimilar Labeling
(June 1, 2016) - Public Sector Healthcare Roundtable Comment letter to U.S. HHS re: Medicare Part-B
(May 6, 2016) - OPERS letter in support of Celltrion's Biologics License Application for a biosimilar infliximab
(Feb. 3, 2016) - OPERS Testifies to US House Democratic Steering and Policy Committee
(Nov. 30, 2015) - Letter of support to U.S. Senate re: FAST Generics Act
(Dec. 21, 2015) - Biosimilars Network Letter to FDA re: Biosimilars Naming Guidance
(Nov. 3, 2015) - OPERS Comment Letter to FDA on biologics naming
(Oct. 27, 2015) - OPERS Comment Letter to John Boehner on projected Medicare Part B Premium Increases
(Oct. 1, 2015) - Joint Letter to Legislators on projected Medicare Part B Premium Increases
(Sept. 30, 2015) - OPERS Comment Letter to HHS on Medicare program; revisions to payment policies
(Sept. 8, 2015) - OPERS Comment Letter to HHS on Medicare program; revisions to payment policies
(Sept. 8, 2015) - OPERS Comment Letter – Additional Q&A Regarding Implementation of BPCIA
(July 9, 2015) - Biosimilars Network Letter to FDA re: Biosimilars Naming
(June 30, 2015) - Letter of Support re: FAST Generics Act of 2015
(June 17, 2015) - Letter to IRS on Excise Tax on High Cost Employer-Sponsored Health Coverage
(May 15, 2015) - Letter to U.S. House of Representatives Energy & Commerce Committee re: 21st Century Cures Initiative
(May 8, 2015) - Letter to FDA on Labeling
(April 27, 2015) - Biosimilar – Burwell letter
(April 27, 2015) - Comments to the FDA on Risk Evaluation and Mitigation Strategy programs
(January 26, 2015)
Below are comment letters submitted by OPERS to various agencies such as the SEC, FTC, IRS, and Treasury.